1809249-37-3

Remdesivir is a nucleoside analogue and is an RNA-dependent RNA polymerase (RdRp) inhibitor. It can synthesize anti-virus by inhibiting viral nucleic acid. The current Chemicalbook bed study for Ebola virus infection has reached stage II. Mice infected with MERS performed much better after receiving this combination therapy, with reduced virus replication and improved lung function. Recent studies have shown that redoxivir has a certain effect on the inhibition of new coronavirus.

Remdesivir is an antiviral drug developed by Gilead Sciences to treat the novel coronavirus (COVID-19). It is the only antiviral drug that has been approved by the United States Food and Drug Administration (FDA) to treat COVID-19. Remdesivir works by blocking the virus from replicating in the body, thus helping to reduce the severity of the disease and shorten the time required for recovery. In clinical trials, Remdesivir was shown to significantly reduce recovery time for hospitalized patients suffering from COVID-19.

Remdesivir is administered intravenously, and can be used in both adults and children. It is generally used in combination with other treatments, such as oxygen therapy, to provide the best chance of recovery. The safety and efficacy of Remdesivir has been established in numerous clinical trials, and the drug has been found to be safe and effective for the treatment of COVID-19.

Remdesivir is an important tool in the fight against the novel coronavirus and can help reduce the duration of hospitalization and improve the chances of recovery for those suffering from COVID-19.